PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463765
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463765
Key Highlights
The optogenetics market was valued at USD 580.7 million in 2023, and it will rise to USD 772.7 million, powering at more than 4.0% compound annual growth rate, by 2030.
This growth is because of the increasing application area of optogenetics in the area of neurosciences as a possible diagnostic tool, due to the technological improvements and increasing utilization of multimodal imaging methods.
The rising incidence of neurological disorders because of several infections, spinal cord injuries, genetic factors, several congenital anomalies, and brain injuries, is boosting the industry's expansion.
Apart from the increasing occurrence of such chronic disorders, the stressful lives, as well as financial problems, will drive the requirement for the diagnosis and treatment of psychiatric issues; here, optogenetics plays a part in tracking the behavior of individuals with such problems.
Approximately 20% of worldwide adolescents and children have psychiatric issues, and the count is rising every day, with suicide being the second-leading cause of death among 15 to 29-year-old individuals.
Key Insights
APAC is likely to advance at the fastest compound annual growth rate in the years to come.
It is expected that the increasing neurological illness burden in Japan and China and the large count of CROs in APAC will further boost the growth of the regional industry during this decade.
North America accounted for the largest share of the industry in 2023, of approximately 55%, and it will remain the largest throughout this decade.
The U.S. led the industry in North America, primarily because of the rising occurrence of severe behavioral conditions, such as schizophrenia and Parkinson's.
Light-emitting diode (LED) is likely to advance at a faster compound annual growth rate in the years to come, because of the benefits of LEDs, such as easier control and low cost.
LEDs are being employed in implants to enable the delivery of untethered light.
In 2023, the channelrhodopsin category was the largest contributor to the industry, and it is likely to remain the largest throughout this decade.
The laser category accounted for the largest share of the industry in 2023, of approximately 60%, and it will remain the largest throughout this decade.
This laser technique is extensively employed in neurosciences and biotechnology to deliver focused optical maser radiations to the targeted area.
With the advancement in technology, portable, compact laser sources are now accessible for diagnostic and clinical laboratories.
The hospitals & clinics category accounted for the largest share of the industry in 2023, and it is likely to continue this trend during this decade.
Hospitals are the primary choice of patients suffering from neurological conditions, because of the benefits these settings provide, such as a comfort-inducing physical environment, comprehensive diagnostic and therapeutic support, trained staff, high-quality services, and advanced devices.
The optogenetics industry is moderately consolidated because of the existence of many large and small companies. Some major companies are currently dominating the industry in terms of share.
Most of these players are involved in tactics like funding in research & development, collaborations, and acquisitions.